Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X+S768I mutations in non-small cell lung cancer: An in silico approaches

被引:1
|
作者
Wang, Jun-Ling [2 ]
Liu, Ming-Sheng [3 ]
Fu, Yu-Dong [4 ]
Kan, Qiang-Bo [4 ]
Li, Chun-Yan [5 ]
Ma, Rong [2 ]
Fang, Zhe-Wei [2 ]
Liu, Hong-Xia [2 ]
Li, Meng-Xian [2 ]
Lv, Jia-Ling [5 ]
Sang, Peng [6 ]
Zhang, Chao [1 ]
Li, Hong-Wei [1 ]
机构
[1] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Yuanlin Rd 1, Qujing 655000, Peoples R China
[2] Kunming Med Univ, Affiliated Qujing Hosp, Clin Lab, Qujing 655000, Peoples R China
[3] Kunming Med Univ, Affiliated Qujing Hosp, Dept Urol Surg, Qujing 655000, Peoples R China
[4] Kunming Med Univ, Affiliated Qujing Hosp, Dept Thorac Surg, Qujing 655000, Peoples R China
[5] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Qujing 655000, Peoples R China
[6] Dali Univ, Sch Life Sci, Dali 671003, Peoples R China
来源
OPEN LIFE SCIENCES | 2023年 / 18卷 / 01期
关键词
epidermal growth factor receptor G719X and S768I mutations; non-small cell lung cancer; molecular dynamics simulation; conformation; free energy landscape; MOLECULAR-DYNAMICS;
D O I
10.1515/biol-2022-0768
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene. However, rare mutations such as G719X and S768I lack standard anti-EGFR targeted therapies. Understanding the structural differences between wild-type EGFR and these rare mutants is crucial for developing EGFR-targeted drugs. We performed a systematic analysis using molecular dynamics simulations, essential dynamics (ED), molecular mechanics Poisson-Boltzmann surface area, and free energy calculation methods to compare the kinetic properties, molecular motion, and free energy distribution between wild-type EGFR and the rare mutants' structures G719X-EGFR, S768I-EGFR, and G719X + S768I-EGFR. Our results showed that S768I-EGFR and G719X + S768I-EGFR have higher global and local conformational flexibility and lower thermal and global structural stability than WT-EGFR. ED analysis revealed different molecular motion patterns between S768I-EGFR, G719X + S768I-EGFR, and WT-EGFR. The A-loop and alpha C-helix, crucial structural elements related to the active state, showed a tendency toward active state development, providing a molecular mechanism explanation for NSCLC caused by EGFR S768I and EGFR G719C + S768I mutations. The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer
    Yusuke Chihara
    Koji Date
    Yoshizumi Takemura
    Nobuyo Tamiya
    Yoshihito Kohno
    Tatsuya Imabayashi
    Yoshiko Kaneko
    Tadaaki Yamada
    Mikio Ueda
    Taichiro Arimoto
    Junji Uchino
    Yoshinobu Iwasaki
    Koichi Takayama
    Investigational New Drugs, 2019, 37 : 291 - 296
  • [42] Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601)
    K Komiyama
    K Kobayashi
    S Minezaki
    F Kotajima
    A Sutani
    T Kasai
    K Mori
    E Hoshi
    N Takayanagi
    S Koyama
    K Eguchi
    M Nakayama
    K Kikuchi
    British Journal of Cancer, 2012, 107 : 1474 - 1480
  • [43] Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer
    Chihara, Yusuke
    Date, Koji
    Takemura, Yoshizumi
    Tamiya, Nobuyo
    Kohno, Yoshihito
    Imabayashi, Tatsuya
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Ueda, Mikio
    Arimoto, Taichiro
    Uchino, Junji
    Iwasaki, Yoshinobu
    Takayama, Koichi
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 291 - 296
  • [44] Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601)
    Komiyama, K.
    Kobayashi, K.
    Minezaki, S.
    Kotajima, F.
    Sutani, A.
    Kasai, T.
    Mori, K.
    Hoshi, E.
    Takayanagi, N.
    Koyama, S.
    Eguchi, K.
    Nakayama, M.
    Kikuchi, K.
    BRITISH JOURNAL OF CANCER, 2012, 107 (09) : 1474 - 1480
  • [45] A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101
    Kasai, Takashi
    Mori, Kiyoshi
    Kishi, Kazuma
    Kaburagi, Takayuki
    Hosomi, Yukio
    Imai, Hisao
    Yamada, Yutaka
    Yomota, Makiko
    Moriguchi, Syuhei
    Seike, Masahiro
    Minato, Koichi
    Gemma, Akihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 867 - 875
  • [46] PHASE I/II TRIAL OF S-1 PLUS DOCETAXEL (DTX) FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): KANTO RESPIRATORY DISEASE STUDY GROUP
    Kasai, Takashi
    Mori, Kiyoshi
    Kobayashi, Kunihiko
    Komiyama, Kenichiro
    Minezaki, Syohei
    Uchida, Yuka
    Hoshi, Eishin
    Koyama, Shinichiro
    Eguchi, Keisuke
    Nakayama, Mitsuo
    Kikuchi, Koji
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1211 - S1212
  • [47] Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913
    Yoshiro Nakahara
    Tsuneo Shimokawa
    Yuki Misumi
    Naoyuki Nogami
    Tetsu Shinkai
    Nobuhiko Seki
    Yukio Hosomi
    Naoya Hida
    Hiroaki Okamoto
    Investigational New Drugs, 2021, 39 : 202 - 209
  • [48] A PHASE I/II STUDY OF COMBINATION CHEMOTHERAPY WITH ERLOTINIB AND S-1 IN PRETREATED NON-SMALL CELL LUNG CANCER (NSCLC): THORACIC ONCOLOGY RESEARCH GROUP (TORG) 0808/0913
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Hida, Naoya
    Hosomi, Yukio
    Seki, Nobuhiko
    Okamoto, Hiroaki
    Eguchi, Kenji
    Shibuya, Masahiko
    Morita, Satoshi
    Shinkai, Tetsu
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1163 - S1163
  • [49] A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-
    Takashi Kasai
    Kiyoshi Mori
    Kazuma Kishi
    Takayuki Kaburagi
    Yukio Hosomi
    Hisao Imai
    Yutaka Yamada
    Makiko Yomota
    Syuhei Moriguchi
    Masahiro Seike
    Koichi Minato
    Akihiko Gemma
    International Journal of Clinical Oncology, 2020, 25 : 867 - 875
  • [50] Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913
    Nakahara, Yoshiro
    Shimokawa, Tsuneo
    Misumi, Yuki
    Nogami, Naoyuki
    Shinkai, Tetsu
    Seki, Nobuhiko
    Hosomi, Yukio
    Hida, Naoya
    Okamoto, Hiroaki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 202 - 209